The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial

被引:79
作者
Horak, F. [2 ]
Zieglmayer, P. [2 ]
Zieglmayer, R. [2 ]
Lemell, P. [2 ]
Collins, L. P. [1 ]
Hunter, M. G. [1 ]
Steiner, J. [3 ]
Lewis, T. [4 ]
Payton, M. A. [1 ]
Perkins, C. M. [1 ]
Pettipher, R. [1 ]
机构
[1] Oxagen Ltd, Abingdon OX14 4RY, Oxon, England
[2] Allergy Ctr Vienna W, Vienna, Austria
[3] Oxford Therapeut Consulting, Brightwell Cum Sotwell, Wallingford, Oxon, England
[4] TLWise Consulting, Cambridge, England
关键词
allergic rhinoconjunctivitis; CRTH2; prostaglandin D-2; OC000459; TH2; CELLS; PROSTAGLANDIN D-2; LYMPHOCYTES; CHALLENGE; FEXOFENADINE; CHEMOTAXIS; ACTIVATION; EFFICACY; RHINITIS; ANTIGEN;
D O I
10.1111/all.12042
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background CRTH2 mediates activation of Th2 cells, eosinophils and basophils in response to prostaglandin D2. The CRTH2 antagonist OC000459 has previously been demonstrated to reduce airway inflammation and improve lung function in moderate persistent asthma. The objective of the present study was to determine the involvement of CRTH2 in promoting nasal and ocular symptoms in allergic subjects exposed to grass pollen. Methods A single centre, randomised, double-blind, placebo-controlled, two-way crossover study was conducted in 35 male subjects allergic to grass pollen comparing OC000459 200 mg bid with placebo for 8 days. Subjects were exposed to grass pollen (=1400 grains/m3) for 6 h on the 2nd and 8th days of treatment and assessed for nasal symptoms, ocular symptoms, other symptoms, nasal secretion weight and rhinomanometry over the 6-h period. After a washout period of 3 weeks, subjects were switched to the alternative treatment for a further 8 days. The trial was registered on the clinical trials.gov database (Identifier NCT01448902). Results During the first treatment period, treatment with OC000459 significantly reduced both nasal and ocular symptoms in allergic subjects compared with placebo after challenge with grass pollen. A significant effect was observed on the 2nd day of dosing which was increased on the 8th day of dosing. The therapeutic effects of OC000459 persisted into the second treatment period despite a 3-week washout phase. The safety profile of OC000459 was similar to that of placebo. Conclusion Treatment with OC000459 was well tolerated and led to a significant and persistent reduction in the symptoms of rhinoconjunctivitis.
引用
收藏
页码:1572 / 1579
页数:8
相关论文
共 50 条
  • [41] Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial
    Benveniste, Olivier
    Hogrel, Jean-Yves
    Belin, Lisa
    Annoussamy, Melanie
    Bachasson, Damien
    Rigolet, Aude
    Laforet, Pascal
    Dzangue-Tchoupou, Gaelle
    Salem, Joe-Elie
    Nguyen, Lee S.
    Stojkovic, Tanya
    Zahr, Noel
    Hervier, Baptiste
    Landon-Cardinal, Oceane
    Behin, Anthony
    Guilloux, Edith
    Reyngoudt, Harmen
    Amelin, Damien
    Uruha, Akinori
    Mariampillai, Kuberaka
    Marty, Benjamin
    Eymard, Bruno
    Hulot, Jean-Sebastien
    Greenberg, Steven A.
    Carlier, Pierre G.
    Allenbach, Yves
    LANCET RHEUMATOLOGY, 2021, 3 (01) : E40 - E48
  • [42] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    LANCET, 2020, 395 (10230) : 1126 - 1136
  • [43] EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial
    Rice, Andrew S. C.
    Dworkin, Robert H.
    McCarthy, Tom D.
    Anand, Praveen
    Bountra, Chas
    McCloud, Philip I.
    Hill, Julie
    Cutter, Gary
    Kitson, Geoff
    Desem, Nuket
    Raff, Milton
    LANCET, 2014, 383 (9929) : 1637 - 1647
  • [44] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
    Garvey, W. Timothy
    Frias, Juan P.
    Jastreboff, Ania M.
    Roux, Carel W. le
    Sattar, Naveed
    Aizenberg, Diego
    Mao, Huzhang
    Zhang, Shuyu
    Ahmad, Nadia N.
    Bunck, Mathijs C.
    Benabbad, Imane
    Zhang, Xiaotian M.
    LANCET, 2023, 402 (10402) : 613 - 626
  • [45] Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
    Koh, Christopher
    Canini, Laetitia
    Dahari, Hare
    Zhao, Xiongce
    Uprichard, Susan L.
    Haynes-Williams, Vanessa
    Winters, Mark A.
    Subramanya, Gitanjali
    Cooper, Stewart L.
    Pinto, Peter
    Wolff, Erin F.
    Bishop, Rachel
    Han, Ma Ai Thanda
    Cotler, Scott J.
    Kleiner, David E.
    Keskin, Onur
    Idilman, Ramazan
    Yurdaydin, Cihan
    Glenn, Jeffrey S.
    Heller, Theo
    LANCET INFECTIOUS DISEASES, 2015, 15 (10) : 1167 - 1174
  • [46] Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
    Lheureux, Stephanie
    Cristea, Mihaela C.
    Bruce, Jeffrey P.
    Garg, Swati
    Cabanero, Michael
    Mantia-Smaldone, Gina
    Olawaiye, Alexander B.
    Ellard, Susan L.
    Weberpals, Johanne I.
    Hendrickson, Andrea E. Wahner
    Fleming, Gini F.
    Welch, Stephen
    Dhani, Neesha C.
    Stockley, Tracy
    Rath, Prisni
    Karakasis, Katherine
    Jones, Gemma N.
    Jenkins, Suzanne
    Rodriguez-Canales, Jaime
    Tracy, Michael
    Tan, Qian
    Bowering, Valerie
    Udagani, Smitha
    Wang, Lisa
    Kunos, Charles A.
    Chen, Eric
    Pugh, Trevor J.
    Oza, Amit M.
    LANCET, 2021, 397 (10271) : 281 - 292
  • [47] PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
    Koren, Michael J.
    Descamps, Olivier
    Hata, Yoshiki
    Hengeveld, Ellen Margo
    Hovingh, G. Kees
    Ikonomidis, Ignatios
    Jensen, Maria D. Radu Juul
    Langbakke, Irene Hedelund
    Martens, Fabrice M. A. C.
    Sondergaard, Anette Luther
    Witkowski, Adam
    Koenig, Wolfgang
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03) : 174 - 183
  • [48] Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETOLOGIA, 2016, 59 (07) : 1412 - 1421
  • [49] OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
    Chapple, Christopher
    Sievert, Karl-Dietrich
    MacDiarmid, Scott
    Khullar, Vik
    Radziszewski, Piotr
    Nardo, Christopher
    Thompson, Catherine
    Zhou, Jihao
    Haag-Molkenteller, Cornelia
    EUROPEAN UROLOGY, 2013, 64 (02) : 249 - 256
  • [50] Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial
    Jones, Jermaine D.
    Rajachandran, Lavanya
    Yocca, Frank
    Risinger, Robert
    De Vivo, Michael
    Sabados, Jeff
    Levin, Frances R.
    Comer, Sandra D.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2023, 49 (01) : 109 - 122